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couplingAbstract Osteoporosis is a common disease characterised by low bone density and brittle bone due
to osteoblast–osteoclast uncoupling. The cellular and molecular mechanisms responsible for
osteoblast–osteoclast coupling lead to the identiﬁcation of novel therapeutic targets. The increasing
evidence for a role for Eph–ephrin signalling in biological processes, including cell–cell interactions,
cell morphology, cell migration, angiogenesis, cancer and bone homeostasis, identiﬁes new molec-
ular pathways and potentially novel therapeutic targets for the treatment of diseases. Recent studies
suggest that the interactions between Eph and ephrin play critical roles in bone cell differentiation
and patterning by exerting dimorphic effects on osteoblast and osteoclast differentiation, resulting
in the intriguing coupling of bone resorption and bone formation. These ﬁndings suggest that inter-
ventions targeting osteoblast–osteoclast coupling by the regulation of the Eph–ephrin bidirectional
signalling according to its biological effects, which results in inhibiting osteoclastic resorption and
promoting osteoblastic formation, may be a promising approach for osteoporosis prevention and
treatment in the near future.
ª 2013 Tehran University of Medical Sciences. Published by Elsevier Ltd. All rights reserved.Open access under CC BY-NC-ND license.Introduction
Osteoblast–osteoclast coupling and osteoporosis
Skeletal remodelling depends on ingenious regulation of osteo-
blast–osteoclast coupling, bone formation by osteoblasts cou-021 58858730x5166.
cn (Y. Tieyi).
this work.
niversity of Medical Sciences. Pub
h/
/j.jmhi.2013.02.002pled to bone resorption by osteoclasts. Loss of the coupling
and consequent disruption of bone homeostasis lead to several
metabolic bone diseases, including osteoporosis, osteopetrosis,
tumour-related bone disease, etc. Osteoporosis is a common
disease characterised by low bone density and brittle bone
due to osteoblast–osteoclast uncoupling and is considered an
important risk for about 55% of people older than 50 years,lished by Elsevier Ltd. Open access under CC BY-NC-ND license.
Eph–ephrin bidirectional signalling: A promising approach for osteoporosis treatment 41while 80% of them are women [1]. A detailed knowledge of
bone biology with molecular insights into osteoblast–osteo-
clast coupling and the orchestrating signalling network has
led to the identiﬁcation of novel therapeutic targets. Osteopo-
rosis therapies fall into two classes, antiresorptive drugs, which
slow down bone resorption, and anabolic drugs, which stimu-
late bone formation [2]. Recent studies suggest that Eph–eph-
rin bidirectional signalling provides an intriguing explanation
of cellular and molecular mechanisms responsible for osteo-
blast–osteoclast coupling [3,4] and maybe a potential target
for osteoporosis treatment.
Eph–ephrin bidirectional signalling
Eph–ephrin bidirectional signalling is a novel ﬁnding in bone
homeostasis in the last several years, providing an intriguing
explanation of cellular and molecular mechanisms responsible
for osteoblast–osteoclast coupling. The Eph receptors were
originally identiﬁed during a screen for tyrosine kinases in-
volved in cancer [5]. The interaction between Eph receptors
and ephrin ligands is bidirectional signalling due to activation
of signalling pathways both in the cell expressing receptor
and in the ligand [6]. Activation of the Eph receptors by
the ephrin ligands is referred to as ‘forward signalling’,
whereas activation of the ephrin ligands by the Eph receptors
is designated
‘reverse signalling’ [7]. The Eph–ephrin bidirectional signal-
ling plays an important role in a number of biological pro-
cesses, including cell–cell interactions, cell morphology, cell
migration, angiogenesis, cancer and bone homeostasis [8].
The regulation of Eph–ephrin bidirectional signalling between
osteoblasts and osteoclasts in bone homeostasis
Using gain- and loss-of-function experiments, Zhao, et al. [9]
demonstrated that reverse signalling through ephrinB2 into
osteoclast precursors suppresses osteoclast differentiation by
inhibiting the osteoclastogenic c-Fos–NFATc1 cascade. Fur-
thermore, forward signalling through EphB4 into osteoblasts
enhances osteogenic differentiation, and overexpression of
EphB4 in osteoblasts increases bone mass in transgenic mice.
Thus, EphB4–ephrinB2 signalling inhibits osteoclast differenti-
ation and promotes osteoblast differentiation, inducing a shift
from bone resorption to bone formation [10]. By contrast, the
EphA2–ephrinA2 signalling stimulates osteoclast differentia-
tion and inhibits osteoblast differentiation through the regula-
tion of RhoA activity [4]. Alendronate inhibits osteoblast
function by stimulation of the ephrinB1 expression in pre-osteo-
clasts, which interact with EphB1/B3 receptors in osteoblasts to
suppress osteoblast differentiation [11]. The pathway-based
genome-wide association analysis in a cohort of 1000 unrelated
US whites suggests the signiﬁcant genetic contribution of the
EphR–ephrinA pathway to femoral neck bone geometry [12].
A previous study indicates that the absence of in b-arrestin de-
creases the gene expression of EphB3–ephrinB1 and EphB4–
ephrinB2 signalling induced by continuous parathyroid
hormone (PTH) in cortical bone with wild-type and b-arrestin
/ mice in models of bone remodelling: a low-calcium diet
and ovariectomy [13]. These ﬁndings suggest that interventions
targeting the Eph–ephrin bidirectional signalling may be useful
for the prevention and treatment of osteoporosis [14].Hypothesis
Osteoporosis is characterised by osteoblast–osteoclast uncou-
pling, increase in bone resorption and decrease in bone for-
mation. The therapeutic targets of anti-resorption or
stimulation of bone formation are considered two main kinds
of treatment for osteoporosis currently. The interactions be-
tween Eph and ephrin play critical roles in bone cell differen-
tiation and patterning by exerting dimorphic effects on
osteoblast and osteoclast differentiation, resulting in the
intriguing coupling of bone resorption and bone formation
[15]. Furthermore, the increasing evidence for a role for
Eph–ephrin signalling in bone remodelling identiﬁes new
molecular pathways and potentially novel therapeutic targets
for the treatment of the metabolic diseases [8]. Hence, novel
treatment strategies are developed that aim to combine inhi-
bition of excessive bone resorption with promotion of bone
formation, in the meanwhile targeting Eph–ephrin signalling.
Our hypothesis is that regulation (increase or decrease) of
expression, activity and afﬁnity of the Eph–ephrin bidirec-
tional signalling according to its biological effects is expected
to be targeted in osteoporosis prevention and treatment in
the near future.
Evaluation of hypothesis
The feasibility of this hypothesis is based on the following
facts:
(1) On the one hand, osteoblasts up-regulate ephrinB2
expression in response to PTH or PTH-related protein
(PTHrP) signalling both in vivo and in vitro [3]. On the
other hand, the speciﬁc blockade of EphB4–ephrinB2
interaction using a peptide inhibitor in osteoblasts sig-
niﬁcantly inhibits mineralisation [8]; in addition, recent
research conﬁrms that EphB4–ephrinB2 signalling
within the osteoblast lineage is required for late stages
of osteoblast differentiation, and further, restricts the
ability of osteoblasts to support osteoclast formation
by a speciﬁc inhibitor, soluble EphB4 (sEphB4) [16].
Besides, the absence of b-arrestin decreases the gene
expression of EphB3–ephrinB1 and EphB4–ephrinB2
signalling induced by continuous PTH in cortical bone
[13]. Therefore, PTH, PTHrP or b-arrestin may target
and stimulate EphB4–ephrinB2 signalling and have efﬁ-
ciency for treating osteoporosis (Graphical Abstract
A).
(2) Contrary to the ‘coupling of stimulator’ of EphB4–eph-
rinB2 signalling, EphA2–ephrinA2 interaction facili-
tates the initiation phase of bone remodelling by
enhancing osteoclast differentiation and suppressing
osteoblast differentiation and acts as a ‘coupling inhib-
itor’ [4,15,17]. Similar to the effect of EphA2–ephrinA2
signalling, the interaction of EphB1/B3 and ephrinB1
suppresses osteoblast differentiation [11]. Therefore,
the speciﬁc drugs that still need to be further elucidated
may target and inhibit EphA2–ephrinA2 (Graphical
Abstract B) and EphB1/B3–ephrinB1 (Graphical
Abstract C) signalling and have efﬁciency for treating
osteoporosis.
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In sum, targeting osteoblast–osteoclast coupling by the regula-
tion of expression, activity and afﬁnity of Eph–ephrin bidirec-
tional signalling according to its biological effects, which
results in inhibiting osteoclastic resorption and promoting
osteoblastic formation, may be a promising approach for oste-
oporosis prevention and treatment in the near future.Overview Box
What do we already know about the subject?
Osteoporosis is a common disease characterised by low
bone density and brittle bone due to osteoblast–osteoclast
uncoupling. A detailed knowledge of bone biology with
molecular insights into osteoblast–osteoclast coupling
and the orchestrating signalling network has led to the
identiﬁcation of novel therapeutic targets.
What does your proposed theory add to the current
knowledge available, and what beneﬁts does it have?
The increasing evidence for a role for Eph–ephrin sig-
nalling in biological processes, including cell–cell interac-
tions, cell morphology, cell migration, angiogenesis,
cancer and bone homeostasis, identiﬁes new molecular
pathways and potentially novel therapeutic targets for
the treatment of diseases. Recent studies suggest that the
interactions between Eph and ephrin play critical roles
in bone cell differentiation and patterning by exerting
dimorphic effects on osteoblast and osteoclast differentia-
tion, resulting in the intriguing coupling of bone resorp-
tion and bone formation. These ﬁndings suggest that
interventions targeting osteoblast–osteoclast coupling,
which results in inhibiting osteoclastic resorption and pro-
moting osteoblastic formation, may be a promising ap-
proach for osteoporosis prevention and treatment in the
near future.
Among numerous available studies, what special further
study is proposed for testing the idea?
To investigate the role of Eph–ephrin bidirectional sig-
nalling in osteoporosis treatment, it is recommended to
perform both in vivo and in vitro experiments using differ-
ent molecules, such as soluble EphB4 (sEphB4) and PTH.
For in vivo experiments, local injection of an adjusted
amount of sEphB4 in the presence and absence of PTH
is proposed, and the formation and function of osteo-
blasts and osteoclasts are tested. The idea can also be
tested in vitro by co-culturing of osteoblasts and osteo-
clasts and treating them with appropriate concentrations
and time periods of sEphB4 co-administered with PTH.
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